Evaluating the effectiveness of adding magnesium chloride to conventional protocol of citrate alkali therapy on kidney stone size


1 Department of Urology, Imam Reza Hospital, AJA University of Medical Sciences, Tehran, Iran

2 Medical Student Research Center, Medical School, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Parseh Radiology Center, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Department of Pediatric Nephrology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran


Background: Potassium citrate (K-Cit) is one of the therapeutic solutions broadly used in patients with urolithiasis. However, recent studies have shown that it is not so effective. Therefore, the goal of our study was to evaluate the effect of a combination of K-Cit - MgCl2oral supplements, on urinary stone size.
Materials and Methods: This study was performed on 70 asymptomatic urolithiasis cases. The supplements included K-Cit and magnesium chloride (MgCl2), purchased from (Merck Company, Germany). The patients were randomly divided into two groups. The urinary stone size was measured in the control group after prescribing K-Cit alone and the treated group with combination of K-Cit and MgCl2for 4 weeks by ultrasonography and also urinary parameter was measured in each groups.
Results: The mean age of patients was 16.26 ± 5.70 years. Hyperoxaluria and hypercalciuria were seen in 70% and 52% of patients, respectively. Initially, the mean urinary stone size was measured in each groups and there is not any significant different. However, we find a significant decrease in urinary stone size in group which is treated with combination of K-Cit and MgCl2for 4 weeks in comparison with control group treated with K-Cit alone in the same duration of therapeutic course (5.1 ± 0.8 vs. 2.5 ± 1.2, P< 0.05). All ultrasonography were performed by one radiologist and device.
Conclusion: Our results suggested that a combination of K-Cit and MgCl2chloride is more effective on decreasing urinary stone size than K-Cit alone.


Kolla SB, Wadhwa P, Aron M. Current status of minimally invasive management of pediatric upper urinary tract calculi. J Indian Assoc Pediatr Surg 2006;11:73.  Back to cited text no. 1
  Medknow Journal  
Lewandowski S, Rodgers AL. Idiopathic calcium oxalate urolithiasis: Risk factors and conservative treatment. Clin Chim Acta 2004;345:17-34.  Back to cited text no. 2
Pak CY. Etiology and treatment of urolithiasis. Am J Kidney Dis 1991;18:624-37.  Back to cited text no. 3
Stapleton FB. Clinical approach to children with urolithiasis. Semin Nephrol 1996;16:389-97.  Back to cited text no. 4
Pearle MS, Calhoun EA, Curhan GC. Urologic diseases in America project: Urolithiasis. J Urol. 2005 Mar. 173(3):848-57.  Back to cited text no. 5
Schwille PO, Schmiedl A, Herrmann U, Fan J, Gottlieb D, Manoharan M, et al. Magnesium, citrate, magnesium citrate and magnesium-alkali citrate as modulators of calcium oxalate crystallization in urine: Observations in patients with recurrent idiopathic calcium urolithiasis. Urol Res 1999;27:117-26.  Back to cited text no. 6
Schwartz BF, Bruce J, Leslie S, Stoller ML. Rethinking the role of urinary magnesium in calcium urolithiasis. J Endourol 2001;15:233-5.  Back to cited text no. 7
Gheissari A, Ziaee A, Farhang F, Farhang F, Talaei Z, Merrikhi A, et al. Evaluating the effectiveness of adding magnesium chloride to conventional protocol of citrate alkali therapy in children with urolithiasis. Int J Prev Med 2012;3:791-7.  Back to cited text no. 8
Assimos DG. Re: Ultrasound acoustic shadow width is an accurate predictor of kidney stone size. J Urol 2015;193:900.  Back to cited text no. 9
Sweetman S, editor. Martindale: The Complete Drug Reference. 34th ed. London: Pharmaceutical Press; 2005.  Back to cited text no. 10
Safarinejad MR. Urinary mineral excretion in healthy Iranian children. Pediatr Nephrol 2003;18:140-4.  Back to cited text no. 11
Sikora P, Zajaczkowska M, Zinkiewicz Z, Wawrzyszuk T. Evaluation of oxalate/creatinine ratio in the second morning urine sample of health school children. Pol Merkur Lekarski 2001;10:271-3.  Back to cited text no. 12
Pak CY, Fuller C, Sakhaee K, Preminger GM, Britton F. Long-term treatment of calcium nephrolithiasis with potassium citrate. J Urol 1985;134:11-9.  Back to cited text no. 13
Mattle D, Hess B. Preventive treatment of nephrolithiasis with alkali citrate – A critical review. Urol Res 2005;33:73-9.  Back to cited text no. 14
Barcelo P, Wuhl O, Servitge E, Rousaud A, Pak CY. Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol 1993;150:1761.  Back to cited text no. 15
Pak CY. Citrate and renal calculi: An update. Miner Electrolyte Metab 1994;20:371-7.  Back to cited text no. 16
Ettinger B, Pak CY, Citron JT, Thomas C, Adams-Huet B, Vangessel A. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 1997;158:2069-73.  Back to cited text no. 17
Zerwekh JE, Odvina CV, Wuermser LA, Pak CY. Reduction of renal stone risk by potassium-magnesium citrate during 5 weeks of bed rest. J Urol 2007;177:2179-84.  Back to cited text no. 18
Brundig P, Berg W, Schneider HJ. The influence of magnesium chloride on blood and urine parameters in calcium oxalate stone patients. Eur Urol 1981;7:97-9.  Back to cited text no. 19
Lee YH, Huang WC, Tsai JY, Huang JK. The efficacy of potassium citrate based medical prophylaxis for preventing upper urinary tract calculi: A midterm followup study. J Urol 1999;161:1453-7.  Back to cited text no. 20
Kato Y, Yamaguchi S, Yachiku S, Nakazono S, Hori J, Wada N, et al. Changes in urinary parameters after oral administration of potassium-sodium citrate and magnesium oxide to prevent urolithiasis. Urology 2004;63:7-11.  Back to cited text no. 21
Pak CY, Koenig K, Khan R, Haynes S, Padalino P. Physicochemical action of potassium-magnesium citrate in nephrolithiasis. J Bone Miner Res 1992;7:281-5.  Back to cited text no. 22
Kohri K, Garside J, Blacklock NJ. The role of magnesium in calcium oxalate urolithiasis. Br J Urol 1988;61:107-15.  Back to cited text no. 23
Liebman M, Costa G. Effects of calcium and magnesium on urinary oxalate excretion after oxalate loads. J Urol 2000;163:1565-9.  Back to cited text no. 24
Tiselius HG, Ahlstrand C, Larsson L. Urine composition in patients with urolithiasis during treatment with magnesium oxide. Urol Res 1980;8:197-206.  Back to cited text no. 25
Lindberg JS, Zobitz MM, Poindexter JR, Pak CY. Magnesium bioavailability from magnesium citrate and magnesium oxide. J Am Coll Nutr 1990;9:48-55.  Back to cited text no. 26
Pinto B, Ruiz-Marcellán FJ, Bernshtam J. Effect of a 5-year treatment program in patients with hyperoxaluric stones. J Urol 1983;130:943-5.  Back to cited text no. 27
Barcelo P, Wuhl O, Servitge E, Rousaud A, Pak CY. Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol 1993;150:1761-4.  Back to cited text no. 28
Ettinger B, Citron JT, Livermore B, Dolman LI. Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol 1988;139:679-84.  Back to cited text no. 29
Tiselius HG; Advisory Board of European Urolithiasis Research and EAU Health Care Office Working Party for Lithiasis. Possibilities for preventing recurrent calcium stone formation: Principles for the metabolic evaluation of patients with calcium stone disease. BJU Int 2001;88:158-68.  Back to cited text no. 30